Ammour Y I, Ryabaya O O, Milovanova A V, Sidorov A V, Shohin I E, Zverev V V, Nasedkina T V
Mechnikov Institute of Vaccines and Sera, Moscow, 105064 Russia.
Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation, Moscow, 115478 Russia.
Mol Biol (Mosk). 2018 Jul-Aug;52(4):659-666. doi: 10.1134/S002689841804002X.
The oncolytic potential of the attenuated mumps virus (MV) vaccine strain Leningrad-3 (L-3) was evaluated in a panel of four human metastatic melanoma cell lines. The lines were shown to be susceptible and permissive to MV infection. Efficient MV replication led to death of melanoma cells, but the effect differed among the cell lines. Possible mechanisms mediating the selectivity of MV L-3 towards the cell lines were explored. Replicative and oncolytic activity of MV was found to depend on the expression pattern of type I interferon genes. None of the melanoma cell lines showed induction of expression of the total spectrum of genes required to inhibit virus replication. Based on the results, MV L-3 was assumed to be a promising oncolytic agent for human melanoma cells.
在一组四种人转移性黑色素瘤细胞系中评估了减毒腮腺炎病毒（MV）疫苗株列宁格勒-3（L-3）的溶瘤潜力。结果表明这些细胞系对MV感染敏感且允许其感染。高效的MV复制导致黑色素瘤细胞死亡，但不同细胞系的效果有所差异。探索了介导MV L-3对这些细胞系具有选择性的可能机制。发现MV的复制和溶瘤活性取决于I型干扰素基因的表达模式。没有一个黑色素瘤细胞系显示出抑制病毒复制所需的全部基因谱的表达诱导。基于这些结果，MV L-3被认为是一种有前景的针对人黑色素瘤细胞的溶瘤剂。
